Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking whether MoonLake Immunotherapeutics can turn its tri-specific IL-17 nanobody into a first-in-class therapy often depends on clues buried in 10-K risk factors and 8-K trial updates. Those documents easily exceed a hundred pages of biotech jargon. Stock Titan’s AI cuts through the noise, delivering MoonLake Immunotherapeutics SEC filings explained simply so you spend time on decisions, not deciphering.
Every submission to EDGAR— from a MoonLake Immunotherapeutics quarterly earnings report 10-Q filing to MoonLake Immunotherapeutics 8-K material events explained— lands here in real time. Our platform pairs each release with AI-powered summaries, expert commentary, and side-by-side financial tables, making understanding MoonLake Immunotherapeutics SEC documents with AI effortless. Need instant visibility into MoonLake Immunotherapeutics insider trading Form 4 transactions? We trigger MoonLake Immunotherapeutics Form 4 insider transactions real-time alerts the moment an officer buys or sells shares.
- MoonLake Immunotherapeutics earnings report filing analysis that spotlights R&D burn and cash runway
- MoonLake Immunotherapeutics annual report 10-K simplified to highlight pipeline milestones and licensing obligations
- MoonLake Immunotherapeutics proxy statement executive compensation details, including equity grants
- MoonLake Immunotherapeutics executive stock transactions Form 4 patterns ahead of catalyst dates
With AI summaries, red-flag detection, and historical comparison tools, Stock Titan turns dense biotechnology disclosures into clear intelligence. Whether you’re vetting dilution risk or reviewing MoonLake Immunotherapeutics insider trading Form 4 transactions before an FDA update, the data you need is always one click away.
MoonLake Immunotherapeutics - Schedule 13G/A summary: This filing reports that Bihua Chen, acting through Cormorant Asset Management-related funds, beneficially owns 1,994,173 Class A Ordinary Shares, representing 3.14% of the outstanding Class A shares. The holder reports shared voting and dispositive power over these shares and no sole voting or dispositive power. The percentage calculation references the issuer's reported outstanding Class A share count of 63,501,402. The filer certifies the securities are held in the ordinary course of business and not to influence control of the issuer.
Kristian Reich, Chief Scientific Officer and director of MoonLake Immunotherapeutics (MLTX), executed an equity exchange on 09/02/2025. He surrendered 1,456 common shares of MoonLake AG in exchange for 48,978 Class A ordinary shares of the issuer, and as part of the transaction 48,978 Class C ordinary shares were automatically cancelled for no consideration. The filing discloses that 10,000 MoonLake AG shares held by the reporting person remain subject to a reverse-vesting schedule that completes on January 18, 2026. The filing also states that JeruCON Beratungsgesellschaft mbH owns 2,974,551 Class A ordinary shares, of which Dr. Reich may be deemed an indirect beneficial owner.
Avoro Capital Advisors LLC and Behzad Aghazadeh filed a Schedule 13G disclosing beneficial ownership of 4,150,000 Class A ordinary shares of MoonLake Immunotherapeutics, representing 6.5% of the class. Avoro reports sole voting and sole dispositive power over these shares and states they were acquired for investment purposes on behalf of Avoro Life Sciences Fund LLC.
The filing identifies Dr. Behzad Aghazadeh as the portfolio manager and controlling person of Avoro with the same voting and dispositive powers. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control. A Joint Filing Agreement is attached as an exhibit.
On 08/05/2025 FMR LLC, the parent of Fidelity Investments, together with Abigail P. Johnson, filed Amendment No. 3 to Schedule 13G for MoonLake Immunotherapeutics (MLTX). The filing discloses beneficial ownership of 5,703,048.73 Class A shares (CUSIP 61559X104) as of 06/30/2025, representing 9.0 % of the outstanding class.
The filer reports sole voting power over 5,700,976.70 shares and sole dispositive power over 5,703,048.73 shares; there is no shared voting or dispositive power. The schedule is submitted under Rule 13d-1(b) with FMR classified as a “HC” (parent holding company/control person) and Johnson as “IN” (individual), indicating a passive investment rather than an attempt to influence control. The certification confirms the shares were acquired and are held in the ordinary course of business. No group arrangements, control-changing intentions, or additional financial terms are disclosed.
FAQ
What is the current stock price of MoonLake Immunotherapeutics (MLTX)?
What is the market cap of MoonLake Immunotherapeutics (MLTX)?
